Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours

G Yadegarfar, L Friend, L Jones, L M Plum, J Ardill, B Taal, G Larsson, K Jeziorski, D Kwekkeboom, J K Ramage, EORTC Quality of Life Group, G Yadegarfar, L Friend, L Jones, L M Plum, J Ardill, B Taal, G Larsson, K Jeziorski, D Kwekkeboom, J K Ramage, EORTC Quality of Life Group

Abstract

Background: Quality of life is an important end point in clinical trials, yet there are few quality of life questionnaires for neuroendocrine tumours.

Methods: This international multicentre validation study assesses the QLQ-GINET21 Quality of Life Questionnaire in 253 patients with gastrointestinal neuroendocrine tumours. All patients were requested to complete two quality of life questionnaires - the EORTC Core Quality of Life questionnaire (QLQ-C30) and the QLQ-GINET21 - at baseline, and at 3 and 6 months post-baseline; the psychometric properties of the questionnaire were then analysed.

Results: Analysis of QLQ-GINET21 scales confirmed appropriate aggregation of the items, except for treatment-related symptoms, where weight gain showed low correlation with other questions in the scale; weight gain was therefore analysed as a single item. Internal consistency of scales using Cronbach's α coefficient was >0.7 for all parts of the QLQ-GINET21 at 6 months. Intraclass correlation was >0.85 for all scales. Discriminant validity was confirmed, with values <0.70 for all scales compared with each other.Scores changed in accordance with alterations in performance status and in response to expected clinical changes after therapies. Mean scores were similar for pancreatic and other tumours.

Conclusion: The QLQ-GINET21 is a valid and responsive tool for assessing quality of life in the gut, pancreas and liver neuroendocrine tumours.

Figures

Figure 1
Figure 1
QLQ-GINET21 scale and single-item mean scores at baseline, and at 3 and 6 months post-baseline (x axis: scale/item; y axis: mean score). The subscripts of 1 and 2 represent Group 1 and Group 2, respectively.

References

    1. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16 (3:885–894.
    1. Bonett DG. Sample size requirements for testing and estimating coefficient alpha. J Educ Behav Stat. 2002;27:335–340.
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11 (3:570–579.
    1. Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;16 (2:167–188.
    1. Cull A, Sprangers M, Bjordal K, Aaronson N, West K, Bottomley A.2002. EORTC Quality of Life Group translation procedure Available at:
    1. Davies AH, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C, Taal B, Blazeby JM, Ramage JK. Development of a disease-specific Quality of Life Questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006;42 (4:477–484.
    1. Davies AHG, Mason T, Stangou e (2003Neuroendocrine tumours of the gut, liver and pancreas: overall survival in a large cohort Gut 52A38
    1. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet. 1973;137 (4:637–644.
    1. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2007;18 (4:775–781.
    1. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105 (12:2563–2569.
    1. Fayers PM. Quality-of-life measurement in clinical trials – the impact of causal variables. J Biopharm Stat. 2004;14 (1:155–176.
    1. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group 2001The EORTC QLQ-C30 Scoring Manual3rd ednEuropean Organisation for Research and Treatment of Cancer: Brussels
    1. Hays RD, Havashi T, Carson S, Ware JE. User's Guide for the Multitrait Analysis Program (MAP) Rand: Santa Monica, Canada; 1988.
    1. Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer. 2001a;94 (3:444–448.
    1. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001b;92 (8:2204–2210.
    1. Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med. 1995;237 (3:269–275.
    1. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8 (7:685–690.
    1. Kavadas V, Blazeby JM, Conroy T, Sezer O, Holzner B, Koller M, Buckels J. Development of an EORTC disease-specific Quality of Life Questionnaire for use in patients with liver metastases from colorectal cancer. Eur J Cancer. 2003;39 (9:1259–1263.
    1. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998;124 (6:1063–1070.
    1. Larsson G, Haglund K, Von Essen L. Distress, quality of life and strategies to ‘keep a good mood' in patients with carcinoid tumours: patient and staff perceptions. Eur J Cancer Care (Engl) 2003;12 (1:46–57.
    1. Larsson G, Sjoden PO, Oberg K, Eriksson B, von Essen L. Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol. 2001;40 (7:825–831.
    1. Larsson G, Sjoden PO, Oberg K, von Essen L. Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Ann Oncol. 1999a;10 (11:1321–1327.
    1. Larsson G, von Essen L, Sjoden PO. Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncol. 1999b;38 (4:481–490.
    1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97 (4:934–959.
    1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9 (1:61–72.
    1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79 (4:813–829.
    1. Nave H, Mossinger E, Feist H, Lang H, Raab H. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129 (2:170–175.
    1. Nunnally J, Bernstein I.1994Psychometric Theory3rd edition edMcGraw-Hill: New York
    1. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Blumberg J, Ruszniewski P. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88 (4:770–776.
    1. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Gut. 2012;61 (1:6–32.
    1. Ramage JK, Davies AH. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003;10 (4:483–486.
    1. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ.1999Prognosis and survival in patients with gastrointestinal tract carcinoid tumors Endocr Relat Cancer 229(6815–821.discussion 822–823
    1. Snow ND, Liddle RA.1995Neuroendocrine tumorsIn Gastrointestinal Cancers: Biology, Diagnosis and Therapy, Rustigi AK (ed), p585., Lippincott-Raven: Philadelphia
    1. Soga J. Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res. 1998;17 (1:3–12.
    1. Soreide JA, van Heerden JA, Thompson GB, Schleck C, Ilstrup DM, Churchward M. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg. 2000;24 (11:1431–1436.
    1. Tabachnik BJ, Fidel LS. Using Multivariate Statistics. Harper and Row: London; 1993.
    1. Vinik E, Carlton CA, Silva MP, Vinik AI. Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas. 2009;38 (3:e87–e95.
    1. Walter SD, Eliasziw M, Donner A. Sample size and optimal designs for reliability studies. Stat Med. 1988;17:101–110.
    1. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T, Ahlman H.1996Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction World J Surg 20(7892–899.discussion 899
    1. Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE. Validity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. Int J Epidemiol. 2002;31 (1:168–174.
    1. Wheeler MH, Maddox P, Maddineni S, Jordan S, Amer K, Butchart E. Surgical treatment of carcinoid tumours. Przegl Lek. 2000;57 (Suppl 5:95–97.
    1. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG, Oberg KE. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17 (4:1111.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren